The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial.
 
Nieves Martinez Chanza
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD
 
Aurelien Carnot
Speakers' Bureau - Janssen Oncology; MSD Oncology
Travel, Accommodations, Expenses - Amgen
 
Philippe Barthélémy
Honoraria - Astellas Pharma; BMS; IPSEN; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Eisai; ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; BMS; IPSEN; Janssen-Cilag; MSD; Pfizer
 
Vinciane Casert
No Relationships to Disclose
 
Lionel Staudacher
No Relationships to Disclose
 
Jan Van Den Brande
No Relationships to Disclose
 
Brieuc Sautois
Honoraria - Janssen; MSD
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb Belgium; Clovis Oncology; Janssen
 
Vincent Vanhaudenarde
No Relationships to Disclose
 
Emmanuel Seront
No Relationships to Disclose
 
Veronique Debien
No Relationships to Disclose
 
Thierry Gil
No Relationships to Disclose
 
Marianne Paesmans
No Relationships to Disclose
 
Nuria Kotecki
No Relationships to Disclose
 
Michail Ignatiadis
Consulting or Advisory Role - Novartis; Seagen
Research Funding - Natera (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent entitled method for determining sensitivity to a CDK4/6 inh filed the 18 05 16 by Universite Libre de Bruxelles, Application No/Patent No 16170146.1-1403
 
Simone Albisinni
Honoraria - Astellas Oncology; Janssen
Consulting or Advisory Role - Astellas Oncology; Janssen
 
Jean Christophe Fantoni
No Relationships to Disclose
 
Thibault Tricard
No Relationships to Disclose
 
Romain Diamond
No Relationships to Disclose
 
Thierry Andre Roumeguere
No Relationships to Disclose
 
Ahmad Awada
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Eisai; Genomic Health; Ipsen; LEO Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen